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Abstract
Background: Dengue is one of the most important vector-borne diseases in the world, causing significant
morbidity and economic impact. In Colombia, dengue is a major public health problem. Departments of La Guajira,
Cesar and Magdalena are dengue endemic areas. The objective of this research is to determine the seroprevalence
and the incidence of dengue virus infection in the participating municipalities from these Departments, and also
establish the association between individual and housing factors and vector indices with seroprevalence and
incidence. We will also assess knowledge, attitudes and practices, and willingness-to-pay for dengue vaccine.
Methods: A cohort study will be assembled with a clustered multistage sampling in 11 endemic municipalities.
Approximately 1000 homes will be visited to enroll people older than one year who living in these areas, who will
be followed for 1 year. Dengue virus infections will be evaluated using IgG indirect ELISA and IgM and IgG capture
ELISA. Additionally, vector indices will be measured, and adult mosquitoes will be captured with aspirators. Ovitraps
will be used for continuous estimation of vector density.
Discussion: This research will generate necessary knowledge to design and implement strategies with a
multidimensional approach that reduce dengue morbidity and mortality in La Guajira and other departments from
Colombian Caribbean.
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Background
Although arboviral diseases, such as Chikungunya and
Zika [1, 2], have recently emerged in the Americas,
dengue is globally the most important of the group of
three viruses, particularly related to both incidence and
the burden of disease. An estimated average of 9221
dengue deaths occurred per year between 1990 and
2013, increasing from a nadir of 8277 (95% uncertainty
estimate 5353–10,649) in 1992, to a peak of 11,302
(6790-13,722) in 2010 [3]. This yielded a total of 576,900
(330,000–701,200) years of life lost to premature mortal-
ity attributable to dengue in 2013 [3]. The incidence of
dengue increased considerably between 1990 and 2013,
with the number of cases more than doubling every
decade, from 8.3 million (3.3 million–17.2 million) appar-
ent cases in 1990, to 58.4 million (23.6 million–121.9
million) apparent cases in 2013 [3]. When disability from
moderate and severe acute dengue, and post-dengue
chronic fatigue are taken into account, 566,000 (186,000–
1.415,000) years lived with disability were attributable to
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dengue in 2013 [3]. Combining fatal and non-fatal out-
comes, dengue was responsible for 1.14 million (0.73
million–1.98 million) disability-adjusted life-years in 2013.
In the South American setting, the consequent costs of
dengue are high. Dengue imposes a substantial economic
and disease burden in Latin American countries, such as
Brazil, Mexico and Colombia, among others [4–8]. In
Brazil, the estimated cost for dengue to communities for
the epidemic season of 2012–2013 was US$ 468 million
(90% CL: 349–590) or US$ 1212 million (90% CL: 904–
1526) after adjusting for under-reporting [6]. For Mexico,
the annual cost, including surveillance and vector control,
was US$170 (95% CL: 151–292) million, or $1.56 (95% CL:
1.38–2.68) per capita, comparable to other countries in the
region, during 2010–2011. In that annual total, $87
(95% CL: 87–209) million or $0.80 per capita (95% CL:
0.62–1.12) is related to illness [8]. In Colombia, during
the epidemic year 2010, 1198.73 DALYs were lost per
million inhabitants versus 83.88 in endemic years were
estimated [4]. The total financial cost of the disease to
communities in Colombia was US$167.8 million for 2010,
US$129.9 million for 2011, and US$131.7 million for 2012.
The cost of mosquito prevention borne by households was
a major cost driver, accounting for 46% of the overall cost
in 2010, 62% in 2011, and 64% in 2012 [4].
In Colombia, dengue is endemic in most of the country
(which is <2200 m.a.s.l.), consistent with the wide distribu-
tion of its main vector Aedes aegypti [9–12]. All the
administrative levels report either autochthonous cases
(>90% of the territories) or imported cases (as occurs in
Bogota, the capital city). Between 2000 and 2011, the an-
nual number of non-severe dengue disease cases reported
in nationwide surveillance data ranged between 22,775
(2000) and 147,670 (2010) [13]. Across the period 2000–
2011, the annual number of severe dengue disease cases
reached a maximum of 9777 (38.3 per 100,000 popula-
tion) in 2010, and a minimum of 1383 in 2011 [13]. In
2014, Colombia reporting 105,356 cases diagnosed by
syndromic surveillance, of which 46,842 cases were con-
firmed by laboratory diagnosis, with 2619 severe cases and
166 deaths [14]. In 2015, there were 94,916 cases diag-
nosed by syndromic surveillance with 1360 severe cases
and 72 deaths [15].
In Colombia, the Caribbean coastal region is particu-
larly endemic for dengue. In this region the La Guajira
department (Fig. 1), is located in the northeast, border-
ing Venezuela. This department reported more than
5000 cases between 2007 and 2013 (2033 in 2013), of
which 250 were severe. Thus, the increase in dengue
cases has been particularly evident in La Guajira, where
Fig. 1 Relative position and map of La Guajira and its municipalities, Colombia, South America
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incidence went from being below the national average to
overcome the incidence observed in the other depart-
ments of Colombia (Fig. 2).
La Guajira is composed of 15 municipalities, all of
which reported dengue cases during 2007–2013 (ranging
7–606 cases per year). In La Guajira, Riohacha, the,
coastal capital city and Maicao (Fig. 1) reported more
than 1500 and 1300 cases during this period, respect-
ively.. In both cities an increasing trend was noted from
85 and 111 cases in 2007, to 591 and 606 cases in 2013.
The La Guajira Department has had all the serotypes of
Dengue virus (DENV) circulating since the 1980s [16].
Surveillance may be incomplete in this area of the
country, and it is likely that dengue cases are under-
recorded [16–18]. Enhanced active surveillance will im-
prove the assessment of the real morbidity of dengue in
La Guajira. There is a paucity of published epidemio-
logical data with no relevant scientific publications on
any aspect of dengue [19]. No research has been con-
ducted to assess the various factors which drive dengue
transmission in this setting [20]. Those factors include edu-
cation, economic income [21], migration and population
flows [22], cross-protection between serotypes [12, 23],
and the environmental factors which have influenced
dengue epidemiology, including climate change [24, 25],
and housing standards [26–28]. All of these are important
in order to develop effective integrated interventions
oriented to reduce transmission and the burden of disease
in a given area. Asymptomatic infections, are not usually
assessed by surveillance systems, but significantly affect
transmission [29]. Some studies have suggested that up to
80% of infected subjects show no signs of disease [29–31].
If all these factors are taken into account, interventions
would likely to be more cost-effective.
The main objective of this research is to determine the
seroprevalence and the incidence (outcome variables) of
DENV infection in eleven municipalities (nine from La
Guajira, one from Magdalena department and one from
Cesar department), as well the association between them
with individual, housing factors and vector indexes (in-
dependent variables). In addition, knowledge, attitudes
and practices, as well as willingness to pay for a dengue
vaccine, will also be assessed.
Methods/design
Design and population
A prospective cohort study will be nested with a cross-
sectional study from a clustered multistage sampling in 11
endemic municipalities: nine in La Guajira (Riohacha,
Albania, Fonseca, San Juan del Cesar, Distracción, Maicao,
Villanueva, Uribia and Manaure), one of Magdalena
(Retén) one of Cesar (Valledupar) to assess seropreva-
lence. Approximately 1000 homes will be visited to
around 5000 people older than one year-old living in these
areas will be invited to participate. Persons planning to
change their place of residence in the next 6 months will
be excluded.
Subjects will be followed during one year. DENV in-
fection will be evaluated using serologic tests and, vector
indexes will be measured. Adult mosquitoes will be
captured with aspirators. Ovitraps will be used for
continuous estimation of vector density.
Sampling and sample size
A multistage cluster sampling will be performed. Initially
there will be a random selection of blocks in each muni-
cipality. These will be visited to conduct a population
census of houses. A random selection of households will
be visited to invite all inhabitants to participate. When a
family does not consent to participate, another house in
the same block will be randomly selected. It is expected
at least 1000 houses in the 11 participating municipal-
ities will be included, which could represent a potential
Fig. 2 Dengue incidence rates in La Guajira compared with the other Departments from Colombia, 2001–2015
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of up to 5000 individuals at an average of five persons
per household.
With this sample size we expect to estimate a sero-
prevalence of 50% (proportion with the largest margin of
error), with an error of 1.38%, with a design effect
(DEFF) equal to 1, and of 1.95%, with a DEFF of 2 [32].
The whole projected population of the participating
municipalities was considered as the universe in these
calculations. The software used in sample size calcula-
tion was EPIDAT 3.1 (free).
Variables
Dependent: dengue incidence and seroprevalence
Incidence
Dengue incidence will be assessed by comparing the base-
line sample (Visit 1) with follow-up (visits 2, 3 and 4,
which are separated by 4 months) using specific tests for
DENV, Panbio®, IgM capture ELISA (sensitivity 93.7%
[95% CI 90–96] and specificity 87.8% [95% CI 82–93])
and IgG capture ELISA (sensitivity 72.8 [95% CI 67–78]
and specificity 95.3% [95% CI 91–98]) [33]. IgG capture
ELISA is calibrated in such way that a positive result
corresponds with a HAI titer higher than 1:1280 which is
considered suggestive of recent infection [34]. An inci-
dence case will be defined as those negative at both tests
in the baseline assessment and positive later by any test.
Seroprevalence
DENV seroprevalence will be determined in the baseline
sample with the indirect ELISA test for IgG with the
Panbio E-DEN 01G and IgM capture tests [35]. Panbio
E-DEN 01G exhibited sensitivity of 100% and specificity
of 98% for IgG detection in serum samples collected
from patients with suspected acute DENV infections,
living in dengue endemic areas, compared with serum
samples from patients with other viral infections [33].
Moreover, this indirect IgG ELISA has been widely used
in different studies from endemic and non-endemic
areas to define seroprevalence status [36–40].
This will be performed following the manufacturer’s
instructions. If any of the two tests is positive, the sub-
ject will be considered to have been previously infected
with DENV.
As a measure of quality control, 100 serum samples
will be randomly selected to validate the IgG test using
PRNT as gold standard.
Independent variables
Individual characteristics such as age, sex, level of educa-
tion, occupation and autorefered human mobility will be
considered as independent variables. Housing character-
istics, the availability of drinking water, the presence of
nets at windows and doors, air conditioning, the number
of individuals who live in the house and family structure,
will also be assessed.
The relative abundance of the vector in homes will be
assessed through the index of positive containers (# of
infested containers/# of inspected water containers), the
proportion of geographic areas calculating the Breteau
index (# of positive containers/# of homes inspected), a
house index (% of house with larvae or pupae) and
ovitrap index. In addition, the extent of vector control
performed by household members or by the secretaries
of health of the municipalities (e.g. insecticide spraying)
will be also measured.
Other variables, including clinical classification of
symptomatic or asymptomatic infection, will be based
on information provided weekly during active surveil-
lance of fever cases in homes and performed by staff
who will monitor the ovitrap will be also evaluated.
These technicians will ask about any fever case in the
family. Febrile patients will be interviewed by a nurse
using a standardized questionnaire and taking a blood
sample for diagnostic tests. Samples obtained from fe-
brile patients will be test with CDC DENV-1-4 real-time
RT-PCR assay and/or IgM ELISA (Panbio) depending of
the day of blood collection.
Knowledge, attitudes and practices (KAP) on dengue
will be evaluated using a questionnaire previously
validated by Cáceres-Manrique et al. [41]. A question-
naire to assess willingness to pay for dengue vaccines
was developed using previously published information
from Vietnam, Thailand and Colombia [42]. A summary
of the variables and the moment of evaluation are pre-
sented in Table 1.
Assessment and follow-up
Participating subjects will be evaluated and followed for
12 months (Fig. 3). At baseline (Visit 1) a structured
Table 1 Variables and moments of evaluation
Information to be collected Moment of evaluation
Demographic and mobility variables and
history of symptoms in the last months
Baseline and every 4 months
(visits 1, 2, 3 and 4).
Blood sampling for serological tests. Baseline and every 4 months
(visits 1, 2, 3 and 4).
Housing characteristics including number
of cohabitants
Baseline
Infestation indexes Baseline and every 4 months
(visits 1, 2, 3 and 4).
Revision of ovitraps Weekly, during a year since
the baseline
Active febrile surveillance including blood
sampling in febrile patients.
Weekly, during a year since
the baseline
Knowledge, attitudes and practices (KAP). Baseline
Questionnaire about willingness to pay
for vaccine.
Baseline
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interview will be conducted and a sample of blood (5–
8.5 ml) will be taken. The questionnaire will include
socio-demographic and mobility variables. A history of
fever in the last 3 months and symptoms of dengue in
the last 15 days will be recorded.
Three follow-up visits will be performed, one every
4 months over the year of the study. The follow-up struc-
tured questionnaire will include sociodemographic and
mobility variables, but also gather information regarding
attendance at healthcare services during the follow-up
period. A blood sample to measure DENV antibodies will
be taken at each of the three follow up visits.
Questions about history of Zika and/or Chikungunya,
previous Yellow Fever vaccination and previous recent
travel to other localities, were also included in the base-
line and/or follow-up questionnaires.
Besides active surveillance of febrile cases, participants
will be asked to attend the local allocated health center
in the municipality for clinical evaluation if fever de-
velops. Where dengue is suspected, a blood sample for a
full blood count and dengue diagnosis, as previously
detailed, will be drawn. This follow-up exercise will be
carried out in coordination and collaboration with the
Secretaries of Health of La Guajira and of the municipal-
ities. Surveillance for identifying symptomatic cases will
be enhanced.
Estimation of the vector relative abundance and housing
factors assessment
On the first visit a structured survey on housing charac-
teristics, family composition, and anti-vector measures
will be performed. An inventory and inspection of the
different types of water containers inside the house, in the
yard and garden will be undertaken to determine whether
they are infested with larvae or pupae. Breteau and house-
hold indices will be calculated utilizing information on the
rates of positive containers. Each home will be georefer-
enced using a Garmin equipment (GPSMAP 64 s).
Calculations of the Aedes indexes will be made at each
follow-up event (Visit 2, 3 and 4). Subjects will be asked
about the anti-vector measures taken against the vector
and inspection will be repeated to estimate indices.
Besides infestation indices based on larvae/pupae
identification, a weekly surveillance of vector eggs will
be conducted based in follow-up of ovitraps. Ovitraps
will be placed in participant houses, developed with
black wide-mouthed containers of 1 liter capacity. After
testing in the Riohacha municipality (Fig. 1), and taking
account of the high temperature and humidity in the
area, it was decided that a qualitative filter paper strip
Boeco® 10 cm wide and 800 ml of water will be placed in
each ovitraps (unpublished data). The ovitrap will be
reviewed weekly to collect neckband filter paper and
replace filter paper. These strips will be transferred to
the laboratory where the eggs will be then counted.
In addition, to assist with monitoring vector infection,
adult mosquitoes will be collected using electric aspirators
Fig. 3 Assessment and follow-up of the cohort
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prokopack John W. Hock [43]. Collections will be made
inside homes in rooms, living rooms, and bathrooms and
around the home in the yard and garden. In each environ-
ment two cycles of aspiration of 5 min each will be made.
At least an adult mosquito collection will be performed in
every home. Specimens captured will be taken to the
laboratory where speciation and sex separation will be
done, using taxonomic keys.
Monitoring of circulating virus in the vector
Female groups of Aedes aegypti, captured during visits
to participating households, will be assessed in order to
establish DENV infection, using a nested generic RT-
PCR for flavivirus screening. [44]. Those recorded as
positive will be evaluated with a real-time RT-PCR for
DENV-1-4 (Fig. 4).
KAP on dengue and the willingness-to-pay for vaccines
On the first visit an adult in each homes, will be
asked to answer the KAP survey to assess knowledge
about the disease, attitude to illness compatible with
dengue, as well as the activities needed to prevent
disease. The structured surveys will also include will-
ingness to pay for vaccines. For this purpose, the
questionnaire was designed assuming two scenarios,
one of 70% efficacy at 10 years and another 95%
efficacy at 30 years, with a range of vaccination
prices between COP$3000 and COP$900,000 (around
US$1 and US$300, respectively), and two vaccination
regimens, one of three doses and another utilizing a
single dose. The evaluated prices are similar to those
considered by other researchers in a previous study
[42]. This questionnaire will include data on the
mean family income.
Fig. 4 Diagnostic algorithm for dengue infection in mosquitoes
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Data collection and statistical analysis
To assist with data management, the forms for data col-
lection for baseline and follow-up visits were designed.
These forms were developed to determine the KAP and
the willingness-to-pay for vaccines and for baseline and
follow-up of subjects. These will be pilot tested, updated
and used in the recruitment stage. An access database
for the electronic storage of information for the project
will be designed. Double digitation will be made of each
available data collection form, and these will be cross-
checked using the Data Compare Package of Epi Info
(TM) 3.5.1. Differences for each field filled will be estab-
lished, and paper printed to check data and arrive at an
audited data base which will be the source for further
analysis. Throughout the process of data management,
periodic comparison of digital records and the final
audited data bases will be made.
A description of the population, the characteristics of
the houses, breeding sites and indexes will be made.
Categorical variables will be recorded as frequencies.
Measures of central tendency (mean or median as distri-
bution) will be used for continuous variables. The sero-
prevalence will be determined and the estimate of the
variance will consider the design effect and 95%
confidence intervals obtained. The cumulative incidence
and incidence density for both the total population and
by age groups will be calculated using year age groups.
The frequency of asymptomatic and symptomatic
infections will be determined.
Bivariate analysis will be undertaken for each of the
dependent variables and compared with possible
independent variables. The Chi square test for categor-
ical variables and the Student t test will be used for
continuous variables with normal distribution or the
Mann-Whitney test for continuous variables with
p <0.05 in the normality test.
Those variables in the bivariate analysis achieving p <
0.20 will be evaluated with multivariate analysis binomial
regression or multilevel analysis as appropriate. The
modeling of the variables will be considering obtaining a
parsimonious final model, including those variables that
have statistical significance (p <0.05) or modifying the
estimated primary endpoint by more than 10%. Analyses
will be performed using Stata version 12.0 statistical
program.
Discussion
Implementing strategies to reduce morbidity and mor-
tality from dengue in endemic areas requires integrated
epidemiological information that would allow an im-
provement in the knowledge on factors associated with
local transmission [45]. This project has a multidimen-
sional approach, which includes human factors, the
vector, the environment and the virus. It includes a
seroprevalence study, which will be the second of its
kind in Colombia using a probabilistic sampling design
[46]. Because it will be the first to include more than
one municipality, the representativeness of the sample
will be increased and allow extrapolation of the results
to larger populations.
It will also be the first study of population-based cohort
that includes such a large sample and covers all age
groups, allowing incidence to be estimated for symptom-
atic and asymptomatic dengue and its determinants.
Asymptomatic cases have great relevance to public health,
since they may act as a reservoir for dengue transmission
[34]. Therefore, serological surveys are necessary to know
the distribution of the transmission determinants.
Moreover, seroprevalence studies are important for the
introduction of interventions such as vaccines. For ex-
ample, the Strategic Advisory Group of Experts (SAGE)
on immunization recommended countries introduction
of the available vaccines only in settings with high
endemicity, as indicated by seroprevalence of 70% or
greater. On the other hand, currently, vaccine is not rec-
ommended when seroprevalence is below 50% [47].
This information together with estimates of the
frequency of symptomatic underreporting of cases by
the system of epidemiological surveillance, as well as,
the perceived demand for vaccines by the population
and circulating serotypes in the different municipalities,
will assist public health officers in their decision making
role [48, 49]. It will help identify vulnerable groups and
modifiable factors in the human population and environ-
ment for which intervention will be useful and age
groups that could benefit from vaccination, once this
becomes available [42].
This study will also provide entomological information
that will be help with the development and implementa-
tion of transmission interventions. The data gathered
can also be nested with other entomological studies such
as explore other secondary vectors, and infection with
other arboviruses (eg. Chikungunya and Zika).
In that sense, ovitraps are implemented in this study
as a sensitive and inexpensive method for detecting the
presence of Ae. aegypti and Ae. albopictus. Monitoring
vector abundance continuously using ovitraps is more
sensitive than adult mosquito traps and more efficient
than larval traps. In Colombia two studies have been
reported using ovitramps [50, 51]. In the first, held in
Cali, lethal ovitraps were used as a vector control
method, but were not evaluated for their potential for
the estimation of vector density or its relationship with
human infection [50]. In the second evaluation was
sustained for a shorter period of time (6 months) in only
one municipality and a few cases of dengue were detected,
which probably limited the power to identify association
between the vector and dengue transmission [51].
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Consequently, this will be the first study in Colombia
to systematically assess ovitraps in a sustained study to
assess vector density, which will be evaluated as potential
predictor of transmission of infection and both febrile and
asymptomatic cases. If an association is established, this
tool could be used at regional and national level, facilitating
surveillance and vector control.
The information gathered will improve knowledge
about community attitudes which will assist in the
design of educational campaigns which aim to involve
the community in vector control. Early recognition of
the disease will be encouraged as a strategy for appropri-
ate management, aiming to reduce morbidity and mor-
tality attributable to these arboviruses in the region.
While population studies have been conducted with
interdisciplinary approaches to identify the determinants
of dengue [52], no other projects of this magnitude have
been conducted for dengue that integrates all the
approaches in the same community.
We expect that this proposal will generate valuable
research which will assist with the design and implemen-
tation of multidimensional strategies to reduce morbid-
ity and mortality caused by dengue in La Guajira and
other departments of the Caribbean region. We hope
that knowledge about the determinants of dengue can
be extrapolated to other endemic regions.
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